Aspartic proteinases of Candida spp.: Role in pathogenicity and antifungal resistance

Mycoses

Volumn 57, Issue 1, 2014, Pages 1-11

  Silva, Naiara C ^a   Nery, Jéssica M ^a   Dias, Amanda L T ^a  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

Author keywords

Antifungal resistance; Aspartic proteinase; Candida spp.; Pathogenicity; Virulence

Indexed keywords

ANTIFUNGAL AGENT; ASPARTIC PROTEINASE;

ANTIFUNGAL RESISTANCE; CANDIDA; GENOME; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

CANDIDA;

ANTIFUNGAL RESISTANCE; ASPARTIC PROTEINASE; CANDIDA SPP.; PATHOGENICITY; VIRULENCE;

ANIMALS; ANTIFUNGAL AGENTS; ASPARTIC ACID PROTEASES; CANDIDA; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; HUMANS; MYCOSES; VIRULENCE;

EID: 84890803226     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12095     Document Type: Review

References (116)

1. Chang HC, Chang JJ, Huang AH, Chang TC. Evaluation of a capacitance method for direct antifungal susceptibility testing of yeasts in positive blood cultures. J Clin Microbiol 2000; 38: 971-6.
2. Selitrennikoff CP. Antifungal proteins. Appl Environ Microbiol 2001; 67: 2883-94.
3. Colombo AL, Nakagawa Z, Valdetaro F, Branchini ML, Kussano EJ, Nucci M. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Med Mycol 2003; 41: 235-9.
4. Sardi JC, Scorzoni L, Bernardi T, Frusco-Almeida AM, Giannini JSM. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013; 62: 10-24.
5. Lai CC, Wang CY, Liu WL, Huang WL, Hsueh PR. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol 2012; 61: 701-4.
6. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grilot R. Int J Antimicrob Agents 2006; 27: 359-66.
7. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2009 patients: data from the porpective antifungal therapy alinace registry. Clin Infect Dis 2009; 48: 1695-703.
8. Alenjo HMC, Aquevedo SA, Guzmán DAM et al. Epidemiologial profile of invasive candidiasis in intensive care units at a university hospital. Rev Clinical Infectol 2011; 28: 118-22.
9. Cornistein W, Mora A, Orellana N, Capparelli FJ, Del Castillo M. Candida: epidemiology and risk factors for non-albicans species. Enferm Infecc Microbiol Clin 2012; 19: 322-9.
10. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
11. Chang MR, Correia FP, Costa LC et al. Candida bloodstream infection: data from a teaching hospital in Mato Grosso do Sul, Brasil. Rev Inst Med Trop Sao Paulo 2008; 50: 265-8.
12. Motta AL, Almeida GMD, Almeida JN Jr, Burattini MN, Rossi F. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis 2010; 14: 441-8.
13. Tamura NK, Negri MF, Bonassoli LA, Svidzinski TI. Fatores de virulência de Candida spp. isoladas de cateteres venosos e mãos de servidores hospitalares. Rev Soc Bras Med Trop 2007; 40: 91-3.
14. Costa E, Inês A, Mendes-Faia A, Saavedra MJ, Mendes-Ferreira A. Potential virulence factors of Candida spp. isolated from clinical and food sources. J Hosp Infect 2010; 75: 236-46.
15. Glolo MP, Svidzinski TIE. Phisiopathogenesis, epidemiology and laboratory diagnosis of candidemia. J Bras Patol Med Lab 2010; 46: 225-34.
16. Chang HC, Chang JJ, Chan SH et al. Evaluation of Etest for direct antifungal susceptibility testing of yeasts in positive blood cultures. J Clin Microbiol 2001; 39: 1328-33.
17. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
18. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998; 42: 1900-5.
19. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
20. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995; 177: 5215-21.
21. Sanglard D, Hube B, Monod M, Odds FC, Gow NAR. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of the Candida albicans causes attenuated virulence. Infect Immun 1997; 65: 3539-46.
22. Calderoni RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001; 9: 327-35.
23. Colombo AL, Guimarães T. Epidemiology of hematogenous infections due to Candida spp. Rev Soc Bras Med Trop 2003; 36: 599-607.
24. Braga-Silva LA, Mesquita DGA, Ribeiro MD, Carvalho SMF, Fracalanzza SEL, Santos ALS. Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidades. Braz J Med Biol Res 2009; 42: 765-70.
25. O'Toole GA, Davey ME. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 2000; 64: 847-67.
26. Seneviratne CJ, Jin L, Samaranayake LP. Biofilm lifestyle of Candida: a mini review. Oral Dis 2008; 14: 582-90.
27. Shimizu MT, Almeida NQ, Fantinato V, Unterkircher CS. Studies on hyaluronidase; chondroitin sulphatase: proteinase and phospholipase secreted by Candida species. Mycoses 1996; 39: 161-7.
28. Abu-Elteen KH, Elkarmi AZ, Hamad M. Characterization of phenotype-based pathogenic determinants de various Candida albicans strains in Jordan. Jpn J Infect Dis 2001; 54: 229-36.
29. Costa CR, Passos XS, Souza LKH, Lucena PA, Fernandes OFL, Silva MRR. Diferences in exoenzyme production and adherence ability of Candida spp. isolates from catheter, blood and oral cavity. Rev Inst Med Trop Sao Paulo 2010; 52: 139-43.
30. Noumi E, Snoussi M, Hentati H et al. Adhesive properties and hydrolytic enzymes of oral Candida albicans strains. Mycopathologia 2010; 169: 269-78.
31. Neugnot V, Moulin G, Dubreucq E, Bigey F. The lypase/acyltransferase from Candida parapsilosis: molecular cloning and characterization of purified recombinant enzymes. Eur J Biochem 2002; 269: 1734-45.
32. Staib F. Serum-proteins as nitrogen source for yeastlike fungi. Sabouraudia 1965; 4: 187-93.
33. Remold H, Fasold H, Staib F. Purification and characterization of a proteolytic enzyme from Candida albicans. Biochim Biophys Acta 1968; 167: 399-406.
34. Staniszewska M, Bondaryk M, Siennicka K, Pilat J, Schaller M, Kurzatkowski W. Role of aspartic proteinases in Candida albicans virulence. Part I. Substrate specificity of aspartic proteinases and Candida albicans pathogenesis. Post Microbiol 2012; 51: 127-35.
35. Hamal P, Dostál J, Raclavský V, Krylová M, Pichová I, Hrušková-Heidingsfeldová O. Secreted aspartate proteinases, a virulence factor of Candida spp.: ocurrence among clinical isolates. Folia Microbiol 2004; 49: 491-6.
36. Hornbach A, Heyken A, Schild L, Hube B, Loffler J, Kursai O. The glycosylphosphatidylinositol-anchored protease Sap9 modulates the interaction of Candida albicans with human neutrophils. Infect Immun 2009; 77: 5216-24.
37. Ray TL, Payne CD. Comparative production and rapid purification of Candida acid proteinase from protein-supplemented cultures. Infect Immun 1990; 58: 508-14.
38. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of gene family. Microbiology 2001; 147: 1997-2005.
39. Monod M, Togni B, Hube B, Sanglard D. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol Microbiol 1994; 13: 357-68.
40. Monod M, Hube B, Hess D, Sanglard D. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology 1998; 144: 2731-7.
41. Felk A, Kretschmar M, Albrecht A et al. Candida albicans hyphal formation and the expression of the efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect Immun 2002; 70: 3689-700.
42. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 400-28.
43. Albrecht A, Felk A, Pichova I et al. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 2006; 281: 688-94.
44. Ortega BP, Torres HC, Tanaca LV, Rodriguéz CH. Phylogeny and evolution of the aspartyl protease family from clinically relevant Candida species. Mem Inst Osvaldo Cruz 2009; 104: 505-12.
45. Eisenhaber B, Schneider G, Wildpaner M, Eisenhaber F. A sensitive predictor for potential GPI lipid modification sites in fungal protein sequences and its application to genome-wide studies for Aspergillus nidulans, Candida albicans, Neurospora crassa, Saccharomyces cerevisiae and Schizosaccharomyces pombe. J Mol Biol 2004; 337: 243-53.
46. Pichova I, Pavlicková L, Dostál J et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inibition with peptidomimetic inhibitors. Eur J Biochem 2001; 268: 2669-77.
47. Zaugg C, Zepellin MB, Reichard U, Sanglard D, Monod M. Secreted aspartic proteinase family of Candida tropicalis. Infect Immun 2001; 69: 405-12.
48. Kaur R, Ma B, Cormack BP. A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata. Proc Natl Acad Sci USA 2007; 104: 7628-33.
49. Silva S, Henriques M, Oliveira R et al. Characterization of Candida parapsilosis infection of an in vitro reconstituted human oral epithelium. Eur J Oral Sci 2009; 117: 669-75.
50. Dagdeviren M, Cerikcioglu N, Karavus M. Acid proteinase, phospolipase and adherence properties of Candida parapsilosis strains isolated from clinical specimens of hospitalised patrients. Mycoses 2005; 48: 321-6.
51. Silva S, Negri M, Henriques M, Oliveira R, Williams D, Azevedo J. Silicone colonization by non-Candida albicans Candida species in the presence of urine. J Med Microbiol 2010; 59: 747-54.
52. De Bernardis F, Arancia S, Morelli L et al. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-8.
53. Lian CH, Da Liu W. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007; 50: 383-90.
54. Phan QT, Belanger PH, Filler SG. Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect Immun 2000; 68: 3485-90.
55. Hube B, Monod M, Schofield DA, Brown AJ, Gow NAR. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 1994; 14: 87-99.
56. Hube B, Ruchel R, Monod M, Sanglard D, Odds FC. Functional aspects of secreted Candida proteinases. Adv Exp Med Biol 1998; 436: 339-44.
57. Schaller M, Korting HC, Schafer W, Bastert J, Chen W, Hube B. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 1999; 34: 169-80.
58. Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6: 915-26.
59. Kvaal C, Lachke SA, Srikantha T, Daniels K, McCoy J, Soll DR. Misexoression of the opaque-phase-specific gene PEP1 (sap1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous infection. Infect Immun 1999; 67: 6652-62.
60. Munro CA, Hube B. Anti-fungal therapy at the HAART of viral therapy. Trends Microlbiol 2002; 10: 173-7.
61. Aoki W, Kitahara N, Miura N. Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in Candida albicans. J Biochem 2011; 150: 431-8.
62. Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Mycol 1996; 7: 55-69.
63. Hube B, Sanglard D, Odds FC et al. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun 1997; 65: 109-22.
64. Khan MSA, Ahmad I, Aqil F, Owais M, Shahid M, Musarrat J. Virulence and pathogenicity of fungal pathogens with special reference to Candida albicans. Ahmad I, Owais M, Shahid M, Aqil F (eds), Combating Fungal Infections: Problems and Remedy. London, New York: Springer Heidelberg Dordrecht, 2010: 21-45.
65. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 1998; 28: 543-54.
66. Green CB, Cheng G, Chandra J, Mukherjee P, Ghannoum MA, Hoyer LL. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human ephitelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 2004; 150: 267-75.
67. Naglik JR, Moyes D, Makwana J et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154: 3266-80.
68. Borg M, Ruchel R. Expression of extracellular acid proteinase by proteolytic Candida spp. during experimental infection of oral mucosa. Infect Immun 1988; 56: 626-31.
69. Schaller M, Schafer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 1998; 29: 605-15.
70. Kantarcioglu AS, Yucel A. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses 2002; 45: 160-5.
71. Schaller M, Bein M, Korting HC et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun 2003; 71: 3227-34.
72. Korting HC, Hube B, Oberbauer S et al. Reduced expression of the hyphal-independent Candida albicans proteinase genes SAP1 andSAP3 in the efg1 mutant is associated with attenuated virulence during infection of oral epithelium. J Med Microbiol 2003; 52: 623-32.
73. Lermann U, Morshhauser J. Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans. Microbiology 2008; 154: 3281-95.
74. Naglik JR, Rodgers CA, Shirlaw PJ et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospolipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469-79.
75. Becker JM, Henry LK, Jiang W, Koltin Y. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect Immun 1995; 63: 4515-8.
76. Hazen KC, Mandell G, Coleman E, Wu G. Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiol Lett 2000; 183: 89-94.
77. Kontoyiannis DP, Tarrand J, Prince R, Samonis G, Rolston KVR. Efect of fluconazole on agar invasion by Candida albicans. J Med Microbiol 2001; 50: 78-82.
78. Krcmery V, Kalavsky E. Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent Pat Antiinfect Drug Discov 2007; 2: 182-7.
79. Araujo R, Espinel-Ingroff A. Antifungal resistance: cellular and molecular mecanisms. Ahmad I, Owais M, Shahid M, Aqil F (eds), Combating Fungal Infections: Problems and Remedy. London, New York: Springer Heidelberg Dordrecht, 2010: 125-46.
80. Peman J, Canton E, Espinel-Ingroff A. Antiiungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009; 7: 453-60.
81. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006; 355: 1154-9.
82. Pappas G, Lerodiakonou V, Falagas ME. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe. Clin Ther 2009; 31: 1595-603.
83. Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-9.
84. Pfaller MA, Andes D, Diekema DJ, Espinel-Igroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-95.
85. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-13.
86. Assistance Guidelines. Infections by Candida in the intensive care unit (ICU) [WWW document], 2012. Albert Einstein, Sociedade Beneficente Israelita Brasileira, mai. URL http://medicalsuite.einstein.br/diretrizes/terapia_intensiva/fungos_e_protocolo_HIAE.pdf [accessed on 23 June 2012].
87. Perlin DS, Balashov S, Park S. Multiplex detection of mutations. Methods Mol Biol 2008; 429: 23-31.
88. Papon N, Noel T, Florent M et al. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR I genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob Agents Chemother 2007; 51: 369-71.
89. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically witn fluconazole. N Engl J Med 1991; 325: 1274-7.
90. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torupsilosis glabrata infections with fluconazole prophylasis in neutropenic bone marrow transplant patients. Antimicrob Agents Chem 1993; 37: 1847-9.
91. Barchiesi F, Calabrese D, Sanglard D et al. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 2000; 44: 1578-84.
92. Rhunke M, Westhausen AS, Morschhauser J. Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patinet with AIDS. J Antimicrob Chemother 2000; 46: 291-5.
93. Silva AP, Miranda IM, Guida A et al. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother 2011; 55: 3546-56.
94. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
95. Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat 1999; 2: 259-69.
96. White TC, Pfaller MA, Rinaldi MG, Smith J, Redding SW. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis 1997; 1: S102-9.
97. Georgopapadakou NH. Infectious disease 2001: drug resistance, new drugs. Drug Resist Updat 2002; 5: 181-91.
98. Lopes A, Rocha G, Vilan A, Guedes MB, Guimarães H. Successful caspofungin treatment of invasive refractory candidiasis - in the extremely low birthweight neonate. Acta Med Port 2010; 23: 719-22.
99. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
100. Wu T, Wright K, Hurst S, Morrison C. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44: 1200-8.
101. Graybill JR, Montalbo E, Kirkpatrick W, Luther MF, Revankar SG, Patterson T. Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Chemother 1998; 42: 2938-42.
102. Vazquez JA, Dembry LM, Sanchez V et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998; 36: 421-6.
103. Fekete-Forgacs K, Gyure L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 2000; 43: 273-9.
104. Mores AU, Souza RD, Cavalca L et al. Enhancement of secretory aspartyl protease production in biofilms of Candida albicans exposed to sub-inhibitory concentrations of fluconazole. Mycoses 2009; 54: 195-201.
105. Navarthna DHMLP, Hornby JM, Hoerrmann N, Parkhurst AM, Duhamel GE, Nickerson KW. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J Antimicrob Chemother 2005; 56: 1156-9.
106. Borg-von Zepelin M, Zaschke K, Gross U, Monod M, Muller FM. Effect of micafungina (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 2002; 48: 148-53.
107. Costa CR, Jesuíno RSA, Lemos JÁ et al. Effects of antifungal agents in Sap activity of Candida albicans isolates. Mycopathologia 2009; 169: 91-8.
108. Kumar R, Shukla PK. Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans. Fungal Biol 2010; 114: 189-97.
109. Seneviratne CJ, Wong SS, Yuen KY et al. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia 2011; 172: 389-95.
110. Schulz B, Weber K, Schmidt A, Borg-von Zepelin M, Ruhnke M. Difference in virulence between fluconazole-susceptible and fluconazole-resistant Candida albicans in a mouse model. Mycoses 2011; 54: 522-30.
111. Barelle CJ, Duncan VMS, Brown AJP, Gow NAR, Odds FC. Azole antifungals induce up-relation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. J Antimicrob Chemoter 2008; 61: 315-22.
112. Ripeau JS, Aumont F, Belhumeur P, Ostrosky-Zeichner L, Rex JH, de Repentigny L. Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother 2002; 46: 3096-100.
113. Copping VMS, Barelle CJ, Hube B, Gow NAR, Brown AJP, Odds FC. Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother 2005; 55: 645-54.
114. Cannon RD, Fischer FJ, Niimi K, Niimi M, Arisawa M. Drug pumping mechanisms in Candida albicans. Jap J Med Mycol 1998; 39: 73-78.
115. Yang Y-L. Virulence factors of Candida species. J Microbiol Immunol Infect 2003; 36: 223-8.
116. Mendes A, Mores AU, Carvalho AP, Rosa RT, Samaranayake LP, Rosa EA. Candida albicans biofilms produce more secreted aspartyl protease than the planktonic cells. Biol Pharm Bull 2007; 30: 1813-5.